Citadel Advisors’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18M | Sell |
797,281
-22,487
| -3% | -$500K | ﹤0.01% | 2450 |
|
|
2025
Q4 | $21.2M | Buy |
819,768
+748,590
| +1,052% | +$17.8M | ﹤0.01% | 2274 |
|
|
2025
Q3 | $1.83M | Buy |
+71,178
| New | +$1.75M | ﹤0.01% | 6248 |
|
|
2025
Q2 | – | Sell |
-1,330,035
| Closed | -$33.5M | – | 14419 |
|
|
2025
Q1 | $33.1M | Buy |
1,330,035
+1,282,548
| +2,701% | +$30.7M | 0.01% | 1500 |
|
|
2024
Q4 | $895K | Sell |
47,487
-399,046
| -89% | -$7.01M | ﹤0.01% | 7278 |
|
|
2024
Q3 | $6.72M | Buy |
446,533
+146,471
| +49% | +$2.5M | ﹤0.01% | 3482 |
|
|
2024
Q2 | $8.58M | Buy |
300,062
+212,384
| +242% | +$6.04M | ﹤0.01% | 2972 |
|
|
2024
Q1 | $2.56M | Buy |
87,678
+79,145
| +928% | +$2.43M | ﹤0.01% | 5047 |
|
|
2023
Q4 | $288K | Sell |
8,533
-74,845
| -90% | -$2.19M | ﹤0.01% | 9252 |
|
|
2023
Q3 | $2.56M | Sell |
83,378
-726,772
| -90% | -$26.2M | ﹤0.01% | 4777 |
|
|
2023
Q2 | $32.5M | Buy |
810,150
+381,750
| +89% | +$15.8M | 0.01% | 1405 |
|
|
2023
Q1 | $17.5M | Buy |
428,400
+141,034
| +49% | +$5.61M | ﹤0.01% | 2070 |
|
|
2022
Q4 | $11.1M | Buy |
287,366
+265,825
| +1,234% | +$12.9M | ﹤0.01% | 2691 |
|
|
2022
Q3 | $1.15M | Buy |
+21,541
| New | +$1.2M | ﹤0.01% | 6691 |
|
|
2022
Q2 | – | Sell |
-107,884
| Closed | -$7.07M | – | 13785 |
|
|
2022
Q1 | $8.23M | Buy |
107,884
+3,094
| +3% | +$206K | ﹤0.01% | 3276 |
|
|
2021
Q4 | $6.3M | Buy |
104,790
+91,990
| +719% | +$5.07M | ﹤0.01% | 3888 |
|
|
2021
Q3 | $717K | Sell |
12,800
-65,514
| -84% | -$3.78M | ﹤0.01% | 9010 |
|
|
2021
Q2 | $4.75M | Buy |
78,314
+32,964
| +73% | +$2.09M | ﹤0.01% | 4554 |
|
|
2021
Q1 | $3.18M | Sell |
45,350
-63,114
| -58% | -$4.51M | ﹤0.01% | 5303 |
|
|
2020
Q4 | $6.49M | Sell |
108,464
-9,198
| -8% | -$539K | ﹤0.01% | 3242 |
|
|
2020
Q3 | $7.07M | Sell |
117,662
-50,441
| -30% | -$2.93M | ﹤0.01% | 2690 |
|
|
2020
Q2 | $8.82M | Buy |
168,103
+83,770
| +99% | +$3.5M | ﹤0.01% | 2373 |
|
|
2020
Q1 | $2.83M | Sell |
84,333
-219,113
| -72% | -$9.1M | ﹤0.01% | 3549 |
|
|
2019
Q4 | $13.7M | Buy |
303,446
+4,424
| +1% | +$188K | 0.01% | 1870 |
|
|
2019
Q3 | $11.4M | Sell |
299,022
-75,602
| -20% | -$3.02M | 0.01% | 2068 |
|
|
2019
Q2 | $16.3M | Buy |
374,624
+192,044
| +105% | +$8.15M | 0.01% | 1629 |
|
|
2019
Q1 | $6.95M | Buy |
182,580
+13,341
| +8% | +$521K | ﹤0.01% | 2525 |
|
|
2018
Q4 | $7.28M | Sell |
169,239
-45,193
| -21% | -$2.11M | ﹤0.01% | 2279 |
|
|
2018
Q3 | $10.5M | Buy |
214,432
+179,795
| +519% | +$7.77M | ﹤0.01% | 2038 |
|
|
2018
Q2 | $1.11M | Buy |
34,637
+10,724
| +45% | +$370K | ﹤0.01% | 5031 |
|
|
2018
Q1 | $745K | Sell |
23,913
-214,654
| -90% | -$7.64M | ﹤0.01% | 5241 |
|
|
2017
Q4 | $10.9M | Buy |
238,567
+177,445
| +290% | +$7.03M | 0.01% | 1646 |
|
|
2017
Q3 | $2.29M | Sell |
61,122
-26,633
| -30% | -$1.07M | ﹤0.01% | 3247 |
|
|
2017
Q2 | $4.19M | Sell |
87,755
-97,599
| -53% | -$4.53M | ﹤0.01% | 2308 |
|
|
2017
Q1 | $8.45M | Buy |
185,354
+108,424
| +141% | +$4.69M | 0.01% | 1563 |
|
|
2016
Q4 | $2.48M | Sell |
76,930
-1,231,599
| -94% | -$41.1M | ﹤0.01% | 2701 |
|
|
2016
Q3 | $44.8M | Buy |
1,308,529
+771,927
| +144% | +$30.2M | 0.05% | 438 |
|
|
2016
Q2 | $18.1M | Buy |
+536,602
| New | +$26.4M | 0.02% | 847 |
|
|
2016
Q1 | – | Sell |
-126,397
| Closed | -$7.39M | – | 7650 |
|
|
2015
Q4 | $9.71M | Buy |
126,397
+35,326
| +39% | +$2M | 0.01% | 1301 |
|
|
2015
Q3 | $3.74M | Buy |
91,071
+89,876
| +7,521% | +$5.5M | ﹤0.01% | 2235 |
|
|
2015
Q2 | $85K | Sell |
1,195
-32,383
| -96% | -$2.55M | ﹤0.01% | 7246 |
|
|
2015
Q1 | $2.98M | Buy |
+33,578
| New | +$3.41M | ﹤0.01% | 2596 |
|
|
2014
Q4 | – | Sell |
-17,748
| Closed | -$1.68M | – | 8667 |
|
|
2014
Q3 | $1.72M | Buy |
17,748
+6,969
| +65% | +$678K | ﹤0.01% | 3020 |
|
|
2014
Q2 | $990K | Sell |
10,779
-1,822
| -14% | -$139K | ﹤0.01% | 3495 |
|
|
2014
Q1 | $882K | Buy |
12,601
+12,573
| +44,904% | +$855K | ﹤0.01% | 3589 |
|
|
2013
Q4 | $2K | Sell |
28
-8,578
| -100% | -$451K | ﹤0.01% | 6909 |
|
|
2013
Q3 | $414K | Buy |
8,606
+6,234
| +263% | +$227K | ﹤0.01% | 4013 |
|
|
2013
Q2 | $69K | Buy |
+2,372
| New | +$68.6K | ﹤0.01% | 5475 |
|
Other funds holding PCRX
DPCM
VPM
VCM
Citadel Advisors's PCRX Position: Q1 2026 in Review
Citadel Advisors reduced its Pacira BioSciences (PCRX) stake by 2.7% in Q1 2026, selling an estimated $500K and leaving 797,281 shares worth $18M. The position accounts for ﹤0.01% of the portfolio, ranked #2450.
Citadel Advisors first reported a position in PCRX in Q2 2013 and has held it in 48 quarters since. The position peaked at $44.8M in Q3 2016. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- Citadel Advisors held 797,281 shares of Pacira BioSciences worth $18M as of Q1 2026.
- Citadel Advisors sold 22,487 Pacira BioSciences shares in Q1 2026, an estimated $500K.
- Pacira BioSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2450 holding.
- Citadel Advisors first reported a position in Pacira BioSciences in Q2 2013 and has held it in 48 quarters since.
- Citadel Advisors's Pacira BioSciences position peaked at $44.8M in Q3 2016.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.